At 6.9% CAGR, the SAM Capnography Equipment Market is projected to be worth US$ 40.91 million by 2028, says Business Market Insights              

According to Business Market Insights’ research, the SAM capnography equipment market was valued at US$ 27.38 million in 2022 and is expected to reach US$ 40.91 million by 2028, registering an annual growth rate of 6.9% from 2022 to 2028. Prevalence of respiratory disorders and clinical benefits of capnography equipment over pulse oximetry are the critical factors attributed to the market expansion.                

Chronic respiratory diseases are prevalent non-communicable diseases worldwide due to the commonness of noxious environmental, occupational, and behavioral inhalation. This spectrum of diseases includes chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis (such as silicosis and asbestosis). The prevalence of respiratory disorders is driving the growth of capnography equipment demand. Capnography is a method of monitoring the concentration or partial pressure of carbon dioxide (CO2). The continuous measurement of human respiratory CO2 by using a capnograph provides valuable information about cardiopulmonary resuscitation, endotracheal tube placement, pulmonary embolism, and procedural sedation. The equipment is also used to obtain information about the effect of air pollution on cardiopulmonary characteristics and the effectiveness of a treatment for a patient with respiratory distress. Changes in the shape of the capnogram are used to diagnose respiratory disease conditions, and changes in end-tidal CO2 (EtCO2)—i.e., the maximum CO2 concentration at the end of each tidal breath—can be used to assess disease severity and response to treatment. So, prevalence of respiratory disorders is expected to drive the market growth.

On the contrary, stringent regulations for approval of capnography equipment hurdles the growth of SAM capnography equipment market.    

• Based on product type, the SAM capnography equipment market is segmented into capnometer and capnography accessories & disposables. The capnography accessories & disposables segment held 53.2% market share in 2022, amassing US$ 14.58 million. It is projected to garner US$ 21.70 million by 2028 to expand at 6.9% CAGR during 2022–2028.  
• Based on technology, the SAM capnography equipment market is segmented into mainstream capnography, sidestream capnography, and microstream capnography. The mainstream capnography segment held 55.8% market share in 2022, amassing US$ 15.27 million. It is projected to garner US$ 22.71 million by 2028 to expand at 6.8% CAGR during 2022–2028.
• Based on application, the SAM capnography equipment market is segmented into cardiac care, trauma and emergency care, procedural sedation, respiratory monitoring, and others. The cardiac care segment held 38.7% market share in 2022, amassing US$ 10.58 million. It is projected to garner US$ 15.79 million by 2028 to expand at 6.9% CAGR during 2022–2028.
• Based on end user, the SAM capnography equipment market is segmented into hospitals, ambulatory surgery center, home care settings, and others. The hospitals segment held 60.3% market share in 2022, amassing US$ 16.52 million. It is projected to garner US$ 24.58 million by 2028 to expand at 6.9% CAGR during 2022–2028.
• Based on country, the SAM capnography equipment market is segmented into Brazil, Argentina, and Rest of SAM. Our regional analysis states that Brazil captured 55.8% market share in 2022. It was assessed at US$ 15.26 million in 2022 and is likely to hit US$  23.16 million by 2028, exhibiting a CAGR of 7.2% during the forecast period.    

Key players dominating the SAM capnography equipment market are BD, Dragerwerk AG & Co. KGaA, General Electric Company, Hill Rom Holding Inc. (Baxter), ICU Medical Inc., Koninklijke Philips N.V., Masimo, Medtronic, Nihon Kohden Corporation, and SCHILLER Americas Inc. among others.  

• In July 2020, Welch Allyn (Hill Rom Holdings, Inc.) announced new product launch namely, "Connex® Vital Signs Monitor" that has intuitive touchscreen that is adaptable for most low-acuity healthcare environments and clinical workflows. The product can also track cardiac activity using 3-or-5 lead ECG monitoring, measure pulse oximeter, non-invasive blood pressure (NIBP), temperature, end-tidal CO2 (EtCO2), respiration, and many more.

• In May 2020, Philips announced partnership with Masimo for integrating measurement technologies into few of its IntelliVue MX-series multi-parameter monitors to help assess cerebral oximetry and ventilation status.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com